QMQingchun Mu

Qingchun Mu

*This is an algorithmically generated author record based on publicly available information.

Qingchun Mu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Haiyan Huang

    Department of Neurosurgery, the First Hospital of Jilin University, Changchun, China

    2 shared publications
  • Peiwen Li

    Department of Neurosurgery The First Hospital of Jilin University, Changchun, Jilin 130000, P.R. China

    2 shared publications
  • Ting Lei

    Department of Neurosurgery The First Hospital of Jilin University, Changchun, Jilin 130000, P.R. China

    2 shared publications
  • Fengbo Yu

    School of Pharmacy, Mudanjiang Medical University, Mudanjiang, Heilongjiang Province, China

    1 shared publication
  • Guihong Li

    Department of Neurosurgery, the First Hospital of Jilin University, Changchun, Jilin Province, China; Department of Neurosurgery, Hongqi Hospital of Mudanjiang Medical University, Mudanjiang, Heilongjiang Province, China

    1 shared publication
  • Haijun Gao

    Department of Neurosurgery, The First Hospital of Jilin University, Changchun, Jilin Province, China

    1 shared publication

Latest Publications

  • Acute lymphoblastic leukemia following temozolomide treatment in a patient with glioblastoma: A case report and review of the literature

    by Pengfei Liu, Peiwen Li, Ting Lei, Limei Qu, Haiyan Huang, Qingchun Mu

    Temozolomide (TMZ) is a second-generation oral alkylating agent that functions against a number of central nervous system neoplasms, and is generally used to treat high-grade gliomas, including anaplastic astrocytoma and glioblastoma multiforme. Therapy-related secondary myelodys-plastic syndrome and acute myeloid leukemia have been reported in patients following prolonged exposure to TMZ. However, TMZ-related acute lymphoblastic leukemia (ALL) is extremely rare. The present study describes the case of an 11-year-old boy with a 3-day history of generalized tonic-clonic seizures and a contrast-enhanced lesion in the left temporooccipital region with focal cystic degeneration, as detected by magnetic resonance imaging. The patient underwent craniotomy and gross-total resection and pathological analysis confirmed the diagnosis of giant cell glioblastoma. Postoperatively, the patient received TMZ-based concurrent chemoradiation during radiotherapy, and developed B-cell ALL 6 months following TMZ treatment. A thorough literature search identified only six published cases of TMZ-related ALL. The chemotherapeutic efficacy of TMZ has been identified, however, its leukemogenic potential should be emphasized among practitioners and patients. Further studies are required to determine the specific pathogenic mechanism of TMZ-related ALL. Close hematological monitoring of patients following TMZ treatment is vital and a high index of suspicion is necessary.


  • Open Access

    Bone marrow mesenchymal stem cell therapy in ischemic stroke: mechanisms of action and treatment optimization strategies

    by Haiyan Huang, Qingchun Mu, Guihong Li, Fengbo Yu, Ting Lei, Haijun Gao, Peiwen Li, Yuxue Sun

    Animal and clinical studies have confirmed the therapeutic effect of bone marrow mesenchymal stem cells on cerebral ischemia, but their mechanisms of action remain poorly understood. Here, we summarize the transplantation approaches, directional migration, differentiation, replacement, neural circuit reconstruction, angiogenesis, neurotrophic factor secretion, apoptosis, immunomodulation, multiple mechanisms of action, and optimization strategies for bone marrow mesenchymal stem cells in the treatment of ischemic stroke. We also explore the safety of bone marrow mesenchymal stem cell transplantation and conclude that bone marrow mesenchymal stem cell transplantation is an important direction for future treatment of cerebral ischemia. Determining the optimal timing and dose for the transplantation are important directions for future research.